Aug 13, 2020
ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection
Jun 22, 2020
Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir
Jun 20, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
May 26, 2020
Glenmark to Commence New Phase 3 Clinical Trial on Combination of Two Anti-viral Drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19 in India
May 14, 2020
Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting
May 12, 2020
Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India
May 05, 2020
Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Apr 23, 2020
CMIC Group Supports Clinical Trials and Manufacturing of Influenza Antiviral Drug “Avigan® Tablet” and Contributes to Accelerating Provision for COVID-19 Patients
Apr 22, 2020
Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19
Apr 15, 2020
Fujifilm accelerates production of its influenza antiviral drug "Avigan® Tablet" for COVID-19
Mar 25, 2020
Juntendo University Research: A New Combination Therapy is Effective in Treating a Rare Blood Cancer Cell Type
Mar 19, 2020
Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients
Dec 04, 2019
First Industry Datasets Submitted to ASH Research Collaborative Data Hub
Oct 25, 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Sep 20, 2019
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
May 30, 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
May 17, 2019
Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
Apr 01, 2019
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
Dec 10, 2018
Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation